Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday July 15.
SandRidge Energy (SD)
There's nothing like a hated stock with a fantastic catalyst. SandRidge Energy (SD) is down 13% since March 19th because of its poor quarter and its bid to buy Arena Resources (ARD). The proposed acquisition has been "murder" on shareholders, especially since the purchase will be made with stock, and the number of SandRidge's shares will increase by 150%, diluting their value. Currently, SandRidge is one of the most heavily shorted stocks out there with 25% of its shares sold short.
However, Cramer sees this list of calamities as an opportunity to buy, because this is a "transformational, positive deal" for the company. The acquisition will enable SandRidge to diversify away from just natural gas with the addition of Arena's domestic oil. Cramer's advice is to hang on until Friday when the deal will close and the artificial selling will stop: "You are getting a terrific moment to buy when the artificial selling pressure ends and the new oilier SandRidge takes over."
There's little wonder now why stocks are rallying. Cramer has marked off more items in his checklist of things that need to happen before investors can be bullish again. He looks forward to a better second half of the year with the passing of financial reforms, a soft landing for China, a stronger euro and solid European banks. He commented on the "hugely successful" Spanish bond auction and the fact that BP (BP) finally seems to be containing the oil spill.
The "bonus" The Street received Thursday was the end of the war between Goldman Sachs (GS) and the SEC. While the $550 million Goldman Sachs needs to pay is hardly "chump change," the company might not even sustain damage from it, and Cramer said the fact the SEC didn't demand a confession of guilt from GS rescued the major investment bank from the many lawsuits and claims that would inevitably have followed an admission of guilt. With the pressure off Goldman, there is significant pressure off stocks in general.
Abbott Laboratories (ABT)
Abbott Laboratories (ABT) has taken a hit for its exposure to Europe, but the saving grace will be its many profitable acquisitions in emerging market countries. The stock has dropped 7.1%, which is not surprising, given the fact that 24% of its revenues are from Europe where governments are planning to cut healthcare budgets as part of their austerity measures.
Abbott's performance is still first-rate; it trades at 10 times earnings with an 12% growth rate, which is double the growth of most of Abbott's peers. Abbott also doesn't have the exposure to generics other drug names have. The company makes Humira, a psoriasis drug which makes up 35% of Abbott's sales and Xience, a stent for coronary artery disease. The company's pipeline is "magnificent" with 75 new products coming in the next 5 years.
Abbott's many acquisitions in emerging market countries comprise 20% of revenues, and the company offers a 3.7% dividend, which it has raised consistently. Cramer doesn't expect a huge blowout quarter when it reports on Wednesday, but thinks numbers will be in-line with expectations and the stock will make a comeback. Cramer suggests buying Abbott under $45.
Jim Cramer was up 31% in 2009. Click here now to sign up for Jim's Action Alerts PLUS and trade alongside him. Special discount for Seeking Alpha users.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.